Treatment for glioblastoma (GBM)
This site is intended for US healthcare professionals only.
Optune® Novocure™

Calendar of events

April 14, 2018

Head for the Cure Foundation
HFTC Race
Columbus, OH

April 14-18, 2018

American Association for Cancer Research
AACR
McCormick Place Chicago, IL

April 21 - 27, 2018

American Academy of Neurology
70th AAN Annual Meeting
Los Angeles, CA

April 21, 2018

American Association for Cancer Research
KC Bike Ride
Kansas City, MO

April 21, 2018

National Brain Tumor Society
Delaware Brain Tumor Walk and 5K Run
Wilmington Riverfront, DE

April 22, 2018

American Brain Tumor Association
BT5K
Chicago, IL

April 28, 2018

Melissa's Race
Sanford, FL

April 29, 2018

Head for the Cure Foundation
HFTC Race
Mid-MO

April 28 - May 2, 2018

American Association of Neurological Surgeons
AANS
New Orleans, LA

May 3-4, 2018

NAMCP Medical Directors Institute
2018 Spring Managed Care Forum
Gaylord Palms, Orlando, FL

May 5, 2018

American Brain Tumor Association
BT5K
Denver, CO

May 5, 2018

Head for the Cure Foundation
HFTC Race
North Texas

May 6, 2018

Race for Hope
Washington, DC

May 12, 2018

American Brain Tumor Association
BT5K
Milford, MI

May 12, 2018

National Brain Tumor Society
Central New Jersey Brain Tumor Walk
Asbury Park, NJ

May 12, 2018

National Brain Tumor Society
San Diego Brain Tumor Walk
San Diego, CA

May 15, 2018

Head for the Cure Foundation
HFTC Race
New York, NY

May 17 - 20, 2018

The Oncology Nursing Society Annual Conference
ONS
Washington, DC

May 19, 2018

American Brain Tumor Association
BT5K
Los Angeles, CA

May 19, 2018

National Brain Tumor Society
Charleston Brain Tumor Walk
Charleston, SC

May 20, 2018

Head for the Cure Foundation
HFTC Race
Des Moines, IA

May 20, 2018

National Brain Tumor Society
Boston Brain Tumor Ride
Boston, MA

May 25 - 27, 2018

Georgia Neurosurgical Society
2018 Annual Spring Meeting
Sea Island, GA

June 1 - 5, 2018

American Society of Clinical Oncology
2018 ASCO Annual Meeting
Chicago, IL

June 2, 2018

American Brain Tumor Association
BT5K
Columbus, OH

June 2, 2018

National Brain Tumor Society
Denver Brain Tumor Walk
Denver, CO

June 24, 2018

National Brain Tumor Society
Bay Area Brain Tumor Walk
San Francisco, CA

June 24, 2018

Head for the Cure Foundation
HFTC Race
St. Louis, MO

June 30, 2018

Head for the Cure Foundation
HFTC Race
Seattle, WA

July 14, 2018

University of Louisville and James Graham Brown Cancer Center
2018 Neuro-Oncology Symposium
Louisville, KY

July 22, 2018

Head for the Cure Foundation
HFTC Race
Omaha, NE

August 5, 2018

National Brain Tumor Society
Northwest Brain Tumor Walk
Portland, OR

August 26, 2018

Head for the Cure Foundation
HFTC Race
Metro Kansas City

September 8, 2018

Head for the Cure Foundation
HFTC Race
NC Triangle

September 15, 2018

Head for the Cure Foundation
HFTC Race
Detroit, MI

October 6, 2018

Head for the Cure Foundation
HFTC Race
Cleveland, OH

October 6-10, 2018

Congress of Neurological Surgeons
2018 Annual Meeting
Houston, TX

October 13, 2018

Head for the Cure Foundation
HFTC Race
Houston, TX

October 21, 2018

Head for the Cure Foundation
HFTC Race
Chicago, IL

October 21 - 24, 2018

American Society for Therapeutic Radiology and Oncology
2018 ASTRO Annual Meeting
San Antontio, TX

October 13, 2018

American Brain Tumor Association
BT5K
Twin Cities, MN

November 1-4, 2018

Advanced Practitioner Society for Hematology and Oncology
JADPRO Live
Hollywood, FL

November 8-9, 2018

American Association of Managed Care Nurses
Fall Managed Care Forum
Las Vegas, NV

November 15 – 18, 2018

Society for Neuro-Oncology
2018 SNO Annual Meeting
New Orleans, LA

OPT-055.5-26


*The NCCN defines good performance as Karnofsky Performance Score (KPS) ≥60. The trial for which the IFU is based used an eligibility criteria of KPS ≥70.
The NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Indications For Use

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).

Optune with temozolomide is indicated for the treatment of adult patients with newly diagnosed, supratentorial glioblastoma following maximal debulking surgery, and completion of radiation therapy together with concomitant standard of care chemotherapy.

For the treatment of recurrent GBM, Optune is indicated following histologically- or radiologically-confirmed recurrence in the supratentorial region of the brain after receiving chemotherapy. The device is intended to be used as a monotherapy, and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted.

Important Safety Information

Contraindications

Do not use Optune in patients with an active implanted medical device, a skull defect (such as, missing bone with no replacement), or bullet fragments. Use of Optune together with implanted electronic devices has not been tested and may theoretically lead to malfunctioning of the implanted device. Use of Optune together with skull defects or bullet fragments has not been tested and may possibly lead to tissue damage or render Optune ineffective.

Do not use Optune in patients that are known to be sensitive to conductive hydrogels. In this case, skin contact with the gel used with Optune may commonly cause increased redness and itching, and rarely may even lead to severe allergic reactions such as shock and respiratory failure.

Warnings and Precautions

Optune can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure (the device manufacturer).

Do not prescribe Optune for patients that are pregnant, you think might be pregnant or are trying to get pregnant, as the safety and effectiveness of Optune in these populations have not been established.

The most common (10%) adverse events involving Optune in combination with temozolomide were thrombocytopenia, nausea, constipation, vomiting, fatigue, medical device site reaction, headache, convulsions, and depression.

The most common (10%) adverse events seen with Optune monotherapy were medical device site reaction and headache.

The following adverse reactions were considered related to Optune when used as monotherapy: medical device site reaction, headache, malaise, muscle twitching, fall and skin ulcer.

Use of Optune in patients with an inactive implanted medical device in the brain has not been studied for safety and effectiveness, and use of Optune in these patients could lead to tissue damage or lower the chance of Optune being effective.

If the patient has an underlying serious skin condition on the scalp, evaluate whether this may prevent or temporarily interfere with Optune treatment.


Please click here to see the Optune Instructions For Use (IFU) for complete information regarding the device's indications, contraindications, warnings, and precautions.

On this site, patient and healthcare professional videos as well as all images labeled as Optune users, caregivers, or healthcare professionals depict actual patients, caregivers, and healthcare professionals. All other depictions of patients and caregivers are actor portrayals.

Indications For Use

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).